Previous studies have suggested a relationship between smoking and Hodgkin's lymphoma (HL). The main objective of this study was to evaluate this potential association with a meta-analysis of observational studies.
INTRODUCTION
Hodgkin's lymphoma (HL) constitutes approximately 10% to 15% of the cases of lymphoma in the United States. HL has a bimodal distribution, affecting mainly adolescents or young adults and adults older than age 55 years. 1 According to Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence rate is 2.8 per 100,000 personyears.
2 Modern chemotherapeutic regimens with or without radiation are associated with high cure rates in patients with HL. 3 However, HL affects individuals during their most productive and reproductive years, and the treatment can be associated with debilitating short-and long-term adverse effects. 4, 5 Little is known about risk factors for the development of HL, and a wide variety of factors have been studied. Among them, the association between smoking and HL has been evaluated with conflicting results. Since smoking-related complications can be preventable, the association between smoking and the development of HL is worth investigating further.
We hypothesized that there is a relationship between smoking status and incidence of HL. Since this question will unlikely be answered by means of a randomized, controlled trial, the main goal of this study was to investigate the epidemiologic relationship, if any, between smoking and HL by using a meta-analysis.
PATIENTS AND METHODS

Literature Search
Two authors independently performed literature searches by using PubMed and the Cochrane Database through December 2010. The keywords used were "(smoking OR tobacco OR cigarette) AND lymphoma." The titles and abstracts of the resulting articles were examined and, after excluding nonrelated articles, full-text articles were retrieved. If an article was selected for inclusion, the references were scrutinized for additional studies.
Inclusion and Exclusion Criteria
An article was relevant if it originated from case-control or cohort studies and reported original data, regardless of language, on the association between cigarette smoking and the development of HL. Any discrepancies between reviewers on inclusion of a study were resolved by joint evaluation of the manuscript. If there were multiple publications from the same study, the most relevant was selected, by using the other publications to clarify methodology, if necessary. Reviews or letters to the editor without original data, editorials, case reports, and cross-sectional studies were excluded.
Data Extraction
Data extraction was performed independently by two reviewers and included author, year of publication, country of origin, sample size, method of ascertainment of smoking, and method of diagnosis of HL. For case-control studies, we extracted years of inclusion, the source and definition of cases and controls, the outcome measured with 95% CIs, and the variables used for matching and adjustment. For cohort studies, we extracted the source of the cohort, years of follow-up, the outcome measured with 95% CIs, and the variables used for adjustment. Any discrepancies were addressed by a joint reevaluation of the original article with a third reviewer.
Quality Assessment
The quality of each study was assessed independently by two reviewers who usedtheNewcastle-OttawaScale(NOS). 6 TheNOSconsistsofthreeparametersof quality: selection, comparability, and exposure (case-control studies) or outcome (cohort studies). The NOS assigns a maximum of four points for selection, two points for comparability, and three points for exposure/outcome. Therefore, nine points reflects the highest quality. Any discrepancies were addressed by a joint reevaluation of the original article with a third reviewer.
Data Synthesis and Analysis
Because the risk of HL is low, the relative risk in prospective cohort studies mathematically approximates the odds ratio (OR), 7 therefore permitting the combination of case-control and cohort studies. The primary outcome in this metaanalysis is reported as OR with 95% CI of developing HL in smokers. The outcome was analyzed for the unadjusted (crude) and the maximally adjusted association between ever, current, and former smokers and HL. We measured the outcome by using the random-effects model. 8 The random-effects model accounts for heterogeneity between studies, which is expected in an analysis of this nature. Subset analyses were performed by study type, age, sex, cigarettes smoked per day, years of smoking, pack-years, and Epstein-Barr virus (EBV) status. WeassessedforheterogeneitybetweenstudiesbyusingtheI 2 statistic
9
;values of25%,50%,and75%representmild,moderate,andsevereheterogeneity,respectively. Since positive studies are more likely to be published than negative ones and the simple observation of a funnel plot is subjective, the trim-and-fill method was used to address publication bias. 10 The trim-and-fill method assumes that the effect sizes of all the studies distribute normally around the center of a funnel plot; if asymmetry is found, it adjusts for the potential effect that nonpublished (imputed) studies might have had on the measured outcome. Intensity and duration of smoking were evaluated by using meta-regression methods. The value assigned to each category was the midpoint for closed categories. For open categories, we assumed a maximum of 60 cigarettes per day and 50 years for intensity and duration of smoking, respectively. All calculations and graphs were obtained by using Comprehensive Meta-Analysis (CMA) version 2.2.050 (Biostat, Englewood, NJ). Data from this meta-analysis are presented in accordance with the checklist proposed by the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group.
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RESULTS
Search Results
A total of 17 articles were selected for our meta-analysis, corresponding to three prospective cohort 12-14 and 14 case-control studies.
15-28 Our search flow is shown in Figure 1 .
Characteristics of the Cohort Studies
The main characteristics of the cohort studies are listed in Table 1 . Studies were published between 2006 and 2008. One study originated from the United States, 13 one from Sweden, 12 and one was a European multinational study.
14 A total of 285 cases of HL in a cohort of 1,228,078 individuals, accounting for approximately 12 million person-years, were included in this meta-analysis. Two studies reported a positive association between smoking and HL. 13, 14 All studies assessed HL diagnosis through cancer registry data and assessed smoking habits through a self-administered questionnaire.
Characteristics of the Case-Control Studies
The main characteristics of the case-control studies are provided in Table 2 
Quality Assessment Results
With regard to case-control studies, 93% were of high quality (NOS score Ͼ 6), with an average NOS score of 7.8. One study had a score of 6. 22 The most common selection bias was less than 100% pathologic assessment of patients with HL in three studies. 16, 22, 25 The most common exposure bias was no designation of nonresponse rates in eight studies (57%). In the cohort studies, all had an NOS score of 8. Excluded articles Reviews Case reports Did not pertain to association between smoking and lymphoma (n = 670) (n = 92) (n = 41) (n = 537)
Excluded articles
No data on Hodgkin's No data on smoking No data on incidence Not enough data to calculate outcome Already included in other (n = 50) (n = 31) (n = 9) (n = 4) (n = 3)
Articles selected for full-text retrieval Articles added after citation search (n = 64) (n = 3)
Fig 1. Search results.
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The most common bias was ascertainment of exposure; all the studies assessed smoking by self-administered questionnaires.
Outcome Results
The crude association analysis showed an increased OR of developing HL in current smokers (OR, 1.37; 95% CI, 1.22 to 1.54; P Ͻ .001), a decreased OR in former smokers (OR, 0.72; 95% CI, 0.61 to 0.86; P Ͻ .001), and no association in ever smokers. The heterogeneity among studies was mild to moderate in all groups. The trim-and-fill analysis identified two imputed studies, which would not have altered our results. The maximally adjusted association analysis showed an increased OR in current (OR, 1.35; 95% CI, 1.17 to 1.56; P Ͻ .001) and ever smokers (OR, 1.13; 95% CI, 1.01 to 1.27; P ϭ .03), but no association was found in former smokers. There was moderate heterogeneity among studies, but no publication bias was identified. Complete results are given in Table 3 .
Subset Analyses
Because of the increased OR of developing HL in current smokers, the subset analyses focused on this group of individuals.
Study type. On the basis of retrospective studies, the OR of HL in current smokers was 1.35 (95% CI, 1.13 to 1.61; P ϭ .001). There was moderate heterogeneity (I 2 ϭ 52.4%) but no publication bias. In cohort studies, the OR of HL in current smokers was 1.56 (95% CI, 1.11 to 2.20; P ϭ .01). There was moderate heterogeneity (I 2 ϭ 54.3%) but no publication bias.
Sex. Five studies reported data on men. 12,17,21,25,28 The OR of HL in male current smokers was 1.78 (95% CI, 1.46 to 2.17; P Ͻ .001; Fig 2B) with minimal heterogeneity (I 2 ϭ 15.0%) and no publication bias. Five studies reported data on women.
12,20,21,25,28 The OR of HL in female current smokers was 1.16 (95% CI, 0.89 to 1.51; P ϭ .28) without heterogeneity (I 2 ϭ 0%). The trim-and-fill analysis detected one imputed study, which would have not affected our results.
Age at HL diagnosis. Six studies 14, [16] [17] [18] 20, 21 reported data on patients according to age. Because of heterogeneity in the reports, the ORs will be reported in patients who were younger than age 30 to 40 years at diagnosis of HL and patients who were older than 30 to 40 years. In younger patients, the OR of HL in current smokers was 1.28 (95% CI, 1.06 to 1.55; P ϭ .01) with mild heterogeneity (I 2 ϭ 21.7%) and no publication bias. In older patients, the OR of HL was 1.77 (95% CI, 1.23 to 2.54; P ϭ .002; Fig 2C) with moderate heterogeneity (I 2 ϭ 61.4%) but no publication bias. Smoking intensity. An empirical cutoff of 20 cigarettes per day was used to facilitate analysis. In current smokers who smoked fewer than 20 cigarettes per day, the OR of HL was 1.27 (95% CI, 1.09 to 1.49; P ϭ .002). There was moderate heterogeneity (I 2 ϭ 39.4%) but no publication bias. In current smokers who smoke more than 20 cigarettes per day, the OR of HL was 1.51 (95% CI, 1.16 to 1.98; P ϭ .002; Fig 3A) . There was moderate heterogeneity (I 2 ϭ 59.5%) but no publication bias. In an exploratory analysis, the OR of HL in current smokers who smoke fewer than 10 cigarettes per day was 1.09 (95% CI, 0.88 to 1.35; P ϭ .45). There was mild heterogeneity (I 2 ϭ 22.5%) and no publication bias. Meta-regression analysis that included 12 studies showed a relative OR (rOR) of 1.007 (95% CI, 1.001 to 1.013; P ϭ .025) per cigarette per day. Hence, the rOR for smoking 20, 40, or 60 cigarettes per day would be 1.15 (95% CI, 1.02 to 1.3), 1.32 (95% CI, 1.04 to 1.68), and 1.52 (95% CI, 1.06 to 2.18), respectively.
Duration of smoking. An empirical cutoff of 20 years of smoking duration was selected. In individuals who smoked for fewer than 20 years, the OR of HL was 1.12 (95% CI, 0.93 to 1.36; P ϭ .23) with moderate heterogeneity (I 2 ϭ 41.1%). In individuals who smoked for more than 20 years, the OR was 1.84 (95% CI, 1.47 to 2.32; P Ͻ .001; Fig 3B) with moderate heterogeneity (I 2 ϭ 64.8%). The trim-and-fill analysis identified two imputed studies, which would have not affected our results. In an exploratory analysis, the OR of HL in individuals who smoked for more than 30 years was 2.04 (95% CI, 1.68 to 2.49; P Ͻ .001). There was no heterogeneity (I 2 ϭ 6.9%) and no publication bias. Meta-regression analysis that included 10 studies showed an rOR of 1.013 (95% CI, 1.006 to 1.019; P Ͻ .001) per year of smoking. Hence, the rORs for smoking for 10, 20, or 30 years would be 1.14 (95% CI, 1.06 to 1.21), 1.3 (95% CI, 1.13 to 1.46), and 1.48 (95% CI, 1.2 to 1.77), respectively.
Number of pack-years. A cutoff of 15 pack-years was used to facilitate analysis. In current smokers who have smoked fewer than 15 pack-years, the OR of HL was 1.15 (95% CI, 0.95 to 1.40; P ϭ .16). There was no heterogeneity (I 2 ϭ 0%) and no publication bias. In individuals who have smoked more than 15 pack-years, the OR was 1.97 (95% CI, 1.53 to 2.54; P Ͻ .001; Fig 3C) . There was moderate heterogeneity (I 2 ϭ 56.5%) but no publication bias. Meta-regression analysis was not performed because of the small number of studies (n ϭ 6).
EBV status. In current smokers, the OR for EBV-positive HL was 2.26 (95% CI, 1.69 to 3.02; P Ͻ .001) without heterogeneity (I 2 ϭ 0%). The trim-and-fill analysis identified two imputed studies, which would not have altered our results. The OR for EBV-negative HL was 1.40 (95% CI, 1.08 to 1.81; P ϭ .01) without heterogeneity (I 2 ϭ 0%). The trim-and-fill analysis identified one imputed study, which would not have altered our results.
DISCUSSION
Although several risk factors for the development of HL have been evaluated, this is a field of ongoing investigation. 1 Cigarette smoking is a known risk factor for cancer incidence and mortality. 29 The current literature does not provide a definitive link between smoking and HL; , an index for assessing heterogeneity; OR, odds ratio.
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www.jco.org hence, the attempt on evaluating this potential association with a meta-analysis. Our study revealed several points worth discussing. First, our study shows a statistical association between current smoking and an increased incidence of HL. Individuals who currently smoke have a 39% higher risk of developing HL than never smokers. Former smokers did not seem to have an increased risk of HL. It is important to note that in the studies included, a uniform definition of former and current smokers was not established. Hence, it is possible there is a threshold after stopping smoking at which the risk of HL decreases; however, there were not enough data to evaluate this further.
In subset analyses on current smokers, men and older individuals had a higher risk of HL. Male sex has been associated with a worse outcome in HL, and it is one of the components of the International Prognostic Score (IPS), a tool for stratifying patients with advanced HL by risk. 30 Our study shows that men who currently smoke have a 78% increased risk of HL. The risk of HL was nonsignificant in women. In our study, older patients who currently smoke had a 76% increased risk of HL. Of note, for the age subanalysis, the age groups did not match perfectly. We have used an age range of youngerthan30to40yearsas"younger"andanagerangeofolderthan30 to 40 years as "older." This approach might have introduced bias into our analysis; however, most of the studies included patients with ages ranging between 15 and 80 years. Therefore, although some overlap is likely between the groups, our finding is unlikely to be the result of unequal age distribution.
Interestingly, there seems to be a direct relationship between higher numbers of cigarettes smoked per day, years of smoking, and pack-years and an increased risk of developing HL. There was no apparent increased risk of HL in individuals who smoke fewer than 10 cigarettes per day, but this risk increased to 27% in individuals who smoke up to 20 cigarettes per day and 51% in people who smoke more than 20 cigarettes per day. In addition, meta-regression analysis showed a linear relationship between intensity of smoking and relative OR of developing HL. Similarly, individuals who have smoked for fewer than 20 years had a nonsignificant 12% risk of HL that increased to 84% if smoking continued for more than 20 years and went up to 104% if smoking continued for more than 30 years. Meta-regression analysis was consistent with these results. Finally, when evaluating number of pack-years, smoking fewer than 15 pack-years did not show an increased risk of HL but smoking more than 15 pack-years increased the risk of HL to 97%. Altogether, these findings show internal
No Association Favors Association consistency and support the validity of our findings. On the basis of our results, not only the intensity but also the duration of smoking seems to play a role in the development of HL. In smaller subset analyses, current smoking was also associated with EBV status and histologic subtypes. Current smokers have a 126% increased risk of developing EBV-positive HL and a 40% increased risk of developing EBV-negative HL. This is suggestive of a relationship between smoking and EBV infection. Given the small number of individuals included in these subanalyses, these findings should be considered preliminary.
B
There are several potential mechanisms that could support smoking as a risk factor for HL. In general, direct oncogenic effects of smoking could be mediated by various chemicals contained in cigarettes such as benzene, formaldehyde, and chromium. 17 More specifically, at the cellular level, smoking has been shown to affect the function of B cells, T cells, natural killer cells, and macrophages, not only potentially promoting but also rendering a microenvironment supportive of lymphomagenesis. [31] [32] [33] [34] In addition, smoking is associated with decreased immunoglobulin production. 35 At the molecular level, smoking inhibits apoptosis by modulating Fas ligand in lymphocytes 36, 37 and promotes activation of nuclear factor-kappa B and other proinflammatory cytokines associated with lymphomagenesis, such as interleukin 6 and tumor necrosis factor ␣. 33 Finally, smoking can induce an immunodeficiency state favoring reactivation of EBV, which could be associated with the development of HL. 17, 18, 21 Further research is needed to better understand these phenomena.
Our study has several strengths. First, it is the largest study to date evaluating the association between smoking and HL. Second, a large majority of the studies included were of high quality. And third, studylevel data allowed meaningful subset analyses. However, our study also has several limitations. First, a few studies did not independently confirm a diagnosis of HL. This may have allowed non-HL patients to be included; however,thiswastheminorityofthestudies,and,insuchstudies,random samplesweretakeninwhichadiagnosisofHLwasdemonstrated.Second, smoking habits were self-reported, which may have introduced a recall bias. More likely, smokers were reported as never smokers than the opposite. Therefore, the association between smoking and HL could be stronger than the one reported here. Third, not all the studies controlled for potential confounding variables, such as HIV infection and socioeconomic status. Fourth, many of the subset analyses, although specified a priori, were performed in small data sets and should be interpreted with caution. Finally, the number of patients from prospective studies could be considered small. However, on the basis of 285 cases found in approximately 12 million person-years, the incidence of HL was approximately 2.4 cases per 100,000 person-years, which is similar to SEER data.
In conclusion, our analysis shows that current cigarette smokers have an increased risk of developing HL. The risk of HL appears to be higher in men, in people older than 30 to 40 years of age, and in people with a higher number of cigarettes smoked per day, number of years smoking, and number of pack-years. The health implications of tobacco smoke are vast, having an impact on almost every organ system. Smoking cessation will have a positive impact on public health and should be advised globally. On the basis of the results of our study, it could also decrease the risk of developing HL.
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